Aurobindo Pharma has posted its 3Q 2013-14 unaudited results. The total operating income is up by 36.3 per cent to Rs 2140.6 crores. The operating profit (EBIDTA) before Fx up 148.5 per cent to Rs 643.8 crores. Profit before tax before Fx is up by 220.7 per cent to Rs 547.7 crores. Profit after tax is up by 354.8 per cent to Rs 417.5 crores. The formulation sales is up by 57.5 per cent to Rs 1436.1 crores. The EBITDA during the quarter has improved by 13.6 per cent on Y-o-Y basis due to improved business mix resulting in decrease in materials consumption, staff costs other expenses to net sales by 9.1 per cent, 0.9 per cent and 5.6 per cent respectively and decline in dossier income by two per cent.
N Govindarajan, Managing Director, Aurobindo Pharma said, “We have had a robust quarter driven by our sustaining base business along with successful launches in the US, translating into better top and bottom line We are confident to sustain the momentum as we foray into strengthening our access into markets, products and technology platforms where we are not dominantly present as we consolidate on our existing businesses.”
EP News Bureau – Mumbai
- Advertisement -
